MD, Medical Director, Oliver Sartor, and Clinical Trial Participant, Vanue B. Lacour Jr. explain the importance of this FDA approval, what it means for people with mCRPC, how Pluvicto differs from Standard of Care (SOC), and when and how it is delivered to patients.
Paid for by Novartis. For more information, visit Pluvicto.com.
